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Abstract
Background Pharmacokinetics and pharmacodynamics of drugs in elderly individuals differ from those in younger adults; 
thus, adverse drug events (ADEs) are common in older patients with polypharmacy because co-existing comorbidities elevate 
the risk of ADEs occurring. However, ADEs have not yet been characterised based on the elderly patients of Japanese origin 
and polypharmacy.
Objective The 100 most commonly reported ADEs were grouped into four classes (Class 1–Class 4) based on elderly patients 
with polypharmacy.
Patients and Methods In this study, logistic regression analysis was performed using cases recorded in the Japanese Adverse 
Drug Event Report (JADER) database.
Results ADEs in elderly patients treated with polypharmacy—in whom the risk of electrolyte abnormalities, renal and res-
piratory disorders, and coagulopathy was high—were categorised as ‘Class 1 [E(+), P(+)]’, while ADEs in elderly patients 
not treated with polypharmacy—in whom the risk of delirium and fall was high—were categorised as ‘Class 2 [E(+), 
P(−)]’. When there was no association with being elderly, ADEs associated with polypharmacy that carried a high risk of 
myelosuppression and infection were categorised as ‘Class 3 [E(−), P(+)]’, and allergic ADEs that were not affected by 
being elderly or polypharmacy, were categorised as ‘Class 4 [E(−), P(−)]’. Class 1 events as well as Class 3 ADEs occurred 
more frequently in females than in males, whereas Class 3 ADEs (deep vein thrombosis and pulmonary embolism) occurred 
more frequently in males.
Conclusions Class 1 and Class 2 ADEs should be investigated in analyses that focus on individual drugs.
Supplementary Information The online version contains 
supplementary material available at https ://doi.org/10.1007/s4080 
1-020-00221 -8.
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Key Points 
Using the Japanese Adverse Drug Event Report 
database, adverse drug events were categorized 
into four classes (Class 1–Class 4) based on age 
(elderly—≥ 70 years) and polypharmacy (six or more 
agents).
Among the adverse drug events associated with elderly 
patients, the risks of electrolyte abnormality, renal 
disorder, respiratory disorder, and coagulopathy were 
associated with polypharmacy (Class 1).
Among the adverse drug events associated with elderly 
patients, the risks of delirium and fall were not associ-
ated with polypharmacy (Class 2).
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1 Introduction
As a result of changes in physiological function that occur 
with aging, pharmacokinetics and organic drug responses 
(i.e. pharmacodynamics) differ between the elderly and the 
non-elderly [1–5]. Because of this, the risk of adverse drug 
events (ADEs) is higher in the elderly than in the non-elderly 
[1–6]. Since co-existing comorbidities tend to increase in 
frequency with age, there is a tendency for polypharmacy 
prescribing for the elderly [2, 3, 7, 8]. Polypharmacy, the 
simultaneous use of multiple medications by patients, has 
been linked to reduced adherence to medication, prolonga-
tion of hospitalisation, readmission to hospital immediately 
after discharge, mortality, ADE incidence, and elevated risks 
of drug interaction [3, 4]. Moreover, follow-up prescriptions 
(‘prescription cascades’) of concomitant drugs for occurring 
ADEs also give rise to polypharmacy [4]. This type of poly-
pharmacy treatment in the elderly, which is linked to adverse 
outcomes, has been reported as a global public health issue 
[9]. ADEs induced by polypharmacy increase dramatically 
in patients prescribed five to six drugs [2].
In this way, aging and polypharmacy increase the risk 
of ADEs. It is said that the geriatric syndromes (such as 
delirium, falling, dizziness, and urinary incontinence) are 
non-specific and do not fit into a single deficit diagnosis 
[10]. In other words, it can be considered that the risk of 
certain ADEs in elderly patients receiving polypharmacy 
increases not because of specific drugs but because of an 
increase in the number of drugs administered. Therefore, we 
hypothesized that the elderly may be vulnerable to certain 
ADEs, given that they have higher sensitivity to drugs. Thus, 
the identification of which ADEs are likely to be caused by 
aging and polypharmacy would make it easier to observe 
these ADEs more closely for managing drug treatment effec-
tively in the elderly.
Focusing on cases recorded in the Japanese Adverse Drug 
Event Report (JADER) database from the perspectives of 
polypharmacy and aging, we grouped the 100 most com-
monly reported ADEs into four classes (Class 1–Class 4) 
and investigated the influence of these two factors on the 
risk of ADEs.
2  Methods
2.1  Database Information
The JADER was downloaded from the Pharmaceuticals 
and Medical Devices Agency website (http://www.info.
pmda.go.jp/fukus ayoud b/CsvDo wnloa d.jsp). JADER is the 
database of collected and published cases of ADEs that 
were reported by pharmaceutical companies and medical 
staff, and is used for pharmacovigilance activities. All 
cases recorded from April 2004 to July 2018 were used. 
The JADER is composed of four tables: a ‘demo’ table, a 
‘drug’ table, a ‘reac’ table, and a ‘hist’ table, across which 
each case is linked by the assignment of a common identi-
fication number. Data on patients such as age and sex are 
presented in the ‘demo’ table, data on drugs used in cases 
are presented in the ‘drug’ table, data on ADEs that have 
occurred in cases are presented in the ‘reac’ table, and 
primary disease data are presented in the ‘hist’ table. For 
this study, we used the ‘demo’, ‘drug’ and ‘reac’ tables. 
The ‘drug involvement’ from the drug table in JADER 
mentions ‘Suspected drug’, ‘Co-administered drug’ or 
‘Interactions’ for each drug. However, this study did not 
use the ‘drug involvement’ information as the study did 
not focus on individual drugs. The study instead examined 
all the registered drugs. The ADEs used in this study were 
entered in the database using the preferred terms (PTs) 
from the Medical Dictionary for Regulatory Activities/J 
(MedDRA/J), version 21.0. All processing was performed 
at the PT level.
2.2  Adverse Drug Events (ADEs)
All ADEs recorded in JADER were extracted from the reac 
table, and the total number of reports was calculated for 
each. We then ranked the top 100 ADE cases according to 
their frequency based on the information that we referred 
to. This study analysed these 100 ADEs. Cases in which 
none of the 100 ADEs were observed were also included as 
a control group.
2.3  Data Cleaning
The data-cleaning procedure is shown in Fig. 1. First, cases 
clearly denoted by ‘sex’ and ‘age’ were extracted from the 
JADER demo table. Then, we used the reac table to pre-
pare combinations of ‘identification number-ADEs-date of 
ADEs,’ applying each combination to a single case. ADEs 
reported with the same identification number were counted 
as different cases. Then, using the common identification 
number for each case, we extracted ‘sex’ and ‘age’ from the 
demo table, ‘drug name (generic name),’ ‘date of start of 
use’ and ‘date of termination of use’ from the drug table, 
and ‘ADEs’ and ‘date of ADEs occurrence’ from the reac 
table. Year, month and day were used to denote the start of 
drug use and the termination of drug use, and for the date of 
ADE occurrence. By excluding drugs that were administered 
before or after the ADE occurrence, the remaining drugs 
were considered to have been used at the time of occurrence. 
Drugs with no clear record of the start or termination dates 
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of use and those that were used at the time of ADE occur-
rence were regarded as patient-use drugs. When different 
dosages of the same drug were included in multiple records 
for a single case, the drug was counted as a single agent. The 
JADER also includes clinical trial data, thus spontaneously 
reported cases were included in the analysis, while clinical 
trial data were excluded.
2.4  Data Analysis
Cases were divided into men and women, and subsequent 
analyses were conducted separately for each sex. We counted 
the number of concomitant drugs for each case. Based on 
previous studies, polypharmacy was defined as cases where 
the patient was treated with six or more concomitant drugs 
and non-polypharmacy cases where the patient was treated 
with less than six drugs [11, 12]. Although ‘elderly’ gener-
ally refers to individuals aged 65 years and older, as age is 
grouped by decade in the JADER, ‘elderly’ was defined as 
patients aged 70 years or more and ‘non-elderly’ was defined 
as those aged less than 70 years [13].
In this study, we used logistic regression analysis to ana-
lyse the factors ‘elderly’ and ‘polypharmacy’, because it 
can be used to simultaneously analyse multiple factors [14]. 
Next, to investigate the influence of elderly and polyphar-
macy, with  xe as the presence or absence of elderly, and  xp 
as the presence or absence of polypharmacy with respect to 
the reporting rate for each ADE in the JADER database, p, 
we performed logistic regression analysis according to Eq. 1:
The natural exponential function of the partial regres-
sion coefficient (ae or ap) derived from logistic regression 
analysis with Eqs. (2) and (3) being the adjusted odds ratio 
(adjusted OR), elderly risk  (ORe) and polypharmacy risk 
 (ORp) were calculated for each ADE. Non-association 
between ‘elderly’ or ‘polypharmacy’ and ADE onset is rep-
resented by OR 1, while it is represented by OR > 1 where 
there is risk of ADE onset. In this study, a significant risk 
was defined as a 95% confidence interval of OR.
2.5  ADE Categorisation
Using  ORe and  ORp derived from logistic regression anal-
ysis, 100 types of ADEs were grouped into four classes 
(Fig. 2). First, ADEs for which  ORe significantly exceeded 1 
were grouped into Classes 1 and 2, and all other ADEs were 
grouped into Classes 3 and 4. Next, of the ADEs categorised 
as Class 1 and Class 2, those in which  ORp significantly 
exceeded 1 were grouped into Class 1 [E(+), P(+)] and the 
remainder into Class 2 [E(+), P(−)]. Again, of the ADEs 
categorised as Class 3 and Class 4, those in which  ORp sig-
nificantly exceeded 1 were grouped into Class 3 [E(−), P(+)] 
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Fig. 1  Data-cleaning procedure. ADE adverse drug event
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3  Results
3.1  ADEs in Identified Cases
Total cases registered in JADER (combinations of identifi-
cation number-ADE-date of ADE) comprised 355,855 men 
and 349,460 women. The average number of drugs that 
the patients used simultaneously was 4.25 ± 4.56, and the 
median age of the study group was 70 years. The 100 most 
common types of ADEs are collated by report number in 
Table 1; these were subsequently targeted for analysis.
3.2  ADEs That are Associated with Both Elderly 
and Polypharmacy: Class 1 [E(+), P(+)]
ADEs categorised as Class 1 are presented by sex in Table 2 
((a) Males, (b) Females). The ADEs in Table 2 were ranked 
in descending order of  ORe and  ORp volume. A total of 19 
and 26 male and female ADE types, respectively, were cate-
gorised as Class 1. Of these, 16 ADE types were categorised 
as common to both males and females.
ORe for males included hypoglycaemia (OR 2.03), brad-
ycardia (OR 2.03), hyperkalaemia (OR 1.76), interstitial 
lung disease (OR 1.74), and hyponatraemia (OR 1.73). For 
females, ADEs included hyperkalaemia (OR 3.68), hypogly-
caemia (OR 3.42), hyponatraemia (OR 3.18), bradycardia 
(OR 2.82), and renal failure (OR 2.49).
ORp for males included hyperkalaemia (OR 1.89), trans-
fusion-related acute lung injury (OR 1.71), dehydration (OR, 
1.71), bradycardia (OR 1.49), and respiratory failure (OR 
1.43). For females, the ADEs included disseminated drug 
interaction (OR 2.26), hyperkalaemia (OR 1.90), transfu-
sion-related acute lung injury (OR 1.89), hypokalaemia (OR 
1.66), and rhabdomyolysis (OR 1.65).
Many of the ADEs categorised as Class 1 were related 
to electrolyte abnormalities, renal and respiratory disor-
ders, and coagulopathy. Comparison of male and female 
ADEs identified as Class 1 revealed that lung disorders, 
increased blood creatinine, and dizziness were significant 
for males only, and that ten ADE types (drug interaction, 
urinary retention, pneumonia aspiration, renal disorder, renal 
impairment, electrocardiogram QT prolonged, decreased 
Fig. 2  Categorisation of adverse 
drug events (ADEs) considering 
elderly and polypharmacy. ORe 
adjusted odds ratio with elderly 
as a factor for the occurrence of 
ADEs, ORp adjusted odds ratio 
with polypharmacy as a factor 
for the occurrence of ADEs. 
E(+), P(+): ADEs where  ORe 
and  ORp significantly exceeded 
1; E(+), P(−): ADEs where 
only  ORe significantly exceeded 
1; E(−), P(+): ADEs where 
only  ORp significantly exceeded 
1; E(−), P(−): ADEs where nei-
ther  ORe nor  ORp significantly 
exceeded 1
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Table 1  Top 100 adverse drug 
event (ADE) types considered 
for analysis
No. ADEs No. ADEs
1 Interstitial lung disease 51 Stomatitis
2 Platelet count decreased 52 Pneumocystis jirovecii pneumonia
3 Hepatic function abnormal 53 Alanine aminotransferase increased
4 Anaphylactic shock 54 Urticaria
5 Neutrophil count decreased 55 Hyponatraemia
6 White blood cell count decreased 56 Blood creatine phosphokinase increased
7 Pyrexia 57 Dizziness
8 Anaemia 58 Aspartate aminotransferase increased
9 Pneumonia 59 Hyperkalaemia
10 Liver disorder 60 Renal disorder
11 Neutropenia 61 Hypertension
12 Drug eruption 62 Bradycardia
13 Diarrhoea 63 Hypokalaemia
14 Renal impairment 64 Anaphylactoid reaction
15 Blood pressure decreased 65 Rash generalised
16 Decreased appetite 66 Delirium
17 Febrile neutropenia 67 Erythema
18 Rash 68 Renal failure
19 Acute kidney injury 69 Pleural effusion
20 Rhabdomyolysis 70 Depressed level of consciousness
21 Thrombocytopenia 71 Urinary retention
22 Pancytopenia 72 Diabetes mellitus
23 Hypoglycaemia 73 Electrocardiogram QT prolonged
24 Cerebral infarction 74 Deep vein thrombosis
25 Nausea 75 Pulmonary embolism
26 Erythema multiforme 76 Dehydration
27 Anaphylactic reaction 77 Melaena
28 Cardiac failure 78 Fall
29 Stevens-Johnson syndrome 79 Drug interaction
30 Haemoglobin decreased 80 Jaundice
31 Altered state of consciousness 81 Herpes zoster
32 Vomiting 82 Blood creatinine increased
33 Shock 83 Lymphoproliferative disorder
34 Seizure 84 Palmar-plantar erythrodysaesthesia syndrome
35 Leukopenia 85 Headache
36 Sepsis 86 Transfusion-related acute lung injury
37 Cerebral haemorrhage 87 Cytomegalovirus infection
38 Dyspnoea 88 Pancreatitis acute
39 Loss of consciousness 89 Lung disorder
40 Drug-induced liver injury 90 Respiratory failure
41 Drug reaction with eosinophilia and 
systemic symptoms
91 Hyperglycaemia
42 Malaise 92 Infection
43 Bone marrow failure 93 Ileus
44 Agranulocytosis 94 Pneumonia aspiration
45 Disseminated intravascular coagulation 95 Toxicity to various agents
46 Gastrointestinal haemorrhage 96 Septic shock
47 Death 97 Tubulointerstitial nephritis
48 Toxic epidermal necrolysis 98 Cellulitis
49 Neuroleptic malignant syndrome 99 Toxic skin eruption
50 Osteonecrosis of jaw 100 Peritonitis
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Table 2  Adverse drug events (ADEs) categorised as Class 1  (ORe and  ORp volumes in descending order)
Underlined ADEs are categorised in a separate Class in the other sex
ORe adjusted odds ratio with elderly as a factor for the occurrence of ADEs, ORp adjusted odds ratio with polypharmacy as a factor for the 
occurrence of ADEs, 95% CI 95% confidence interval of  ORe and  ORp, Female Class class in which ADEs common in females are categorised, 
Male Class class in which ADEs common in males are categorised
(a) Male cases
No. ADEs ORe (95% CI) ORp (95% CI) Female class
1 Hyperkalaemia 1.76 (1.54–2.02) 1.89 (1.65–2.16) 1
2 Bradycardia 2.03 (1.77–2.32) 1.49 (1.30–1.70) 1
3 Hypoglycaemia 2.03 (1.86–2.22) 1.29 (1.18–1.41) 1
4 Transfusion-related acute lung injury 1.43 (1.25–1.64) 1.71 (1.49–1.97) 1
5 Hyponatraemia 1.73 (1.50–1.99) 1.29 (1.11–1.49) 1
6 Interstitial lung disease 1.74 (1.67–1.82) 1.17 (1.12–1.23) 1
7 Dehydration 1.18 (1.00–1.40) 1.71 (1.44–2.02) 1
8 Hypokalaemia 1.48 (1.26–1.74) 1.36 (1.15–1.60) 1
9 Lung disorder 1.48 (1.28–1.72) 1.31 (1.12–1.53) 2
10 Respiratory failure 1.33 (1.14–1.56) 1.43 (1.21–1.68) 1
11 Renal failure 1.41 (1.23–1.63) 1.33 (1.15–1.55) 1
12 Altered state of consciousness 1.29 (1.17–1.42) 1.41 (1.28–1.56) 1
13 Anaemia 1.45 (1.31–1.59) 1.20 (1.08–1.33) 1
14 Thrombocytopenia 1.50 (1.35–1.66) 1.13 (1.02–1.26) 1
15 Blood creatinine increased 1.36 (1.15–1.62) 1.24 (1.03–1.49) 2
16 Acute kidney injury 1.20 (1.10–1.30) 1.36 (1.25–1.47) 1
17 Dizziness 1.30 (1.12–1.50) 1.22 (1.05–1.43) 2
18 Pancytopenia 1.24 (1.13–1.37) 1.12 (1.00–1.24) 1
19 Blood pressure decreased 1.10 (1.02–1.18) 1.16 (1.07–1.26) 1
(b) Female cases
No. ADEs ORe (95% CI) ORp (95% CI) Male class
1 Hyperkalaemia 3.68 (3.12–4.37) 1.90 (1.64–2.21) 1
2 Hyponatraemia 3.18 (2.79–3.64) 1.65 (1.45–1.86) 1
3 Hypoglycaemia 3.42 (3.10–3.78) 1.47 (1.34–1.61) 1
4 Bradycardia 2.82 (2.46–3.24) 1.43 (1.25–1.64) 1
5 Renal failure 2.49 (2.08–2.98) 1.61 (1.35–1.91) 1
6 Dehydration 2.48 (2.05–3.01) 1.60 (1.32–1.93) 1
7 Acute kidney injury 2.35 (2.15–2.58) 1.54 (1.41–1.69) 1
8 Hypokalaemia 2.16 (1.89–2.48) 1.66 (1.45–1.90) 1
9 Drug interaction 1.43 (1.24–1.65) 2.26 (1.96–2.61) 3
10 Transfusion-related acute lung injury 1.61 (1.38–1.88) 1.89 (1.62–2.21) 1
11 Urinary retention 2.32 (1.96–2.76) 1.26 (1.06–1.50) 2
12 Pneumonia aspiration 2.08 (1.66–2.61) 1.38 (1.10–1.74) 2
13 Renal disorder 2.04 (1.74–2.39) 1.25 (1.05–1.47) 4
14 Renal impairment 2.04 (1.86–2.23) 1.21 (1.10–1.33) 2
15 Electrocardiogram QT prolonged 1.72 (1.48–1.99) 1.42 (1.22–1.66) 3
16 Altered state of consciousness 1.71 (1.56–1.87) 1.40 (1.27–1.53) 1
17 Decreased appetite 1.84 (1.65–2.06) 1.21 (1.07–1.35) 2
18 Rhabdomyolysis 1.18 (1.07–1.30) 1.65 (1.49–1.83) 3
19 Cardiac failure 1.70 (1.53–1.89) 1.12 (1.00–1.25) 2
20 Anaemia 1.48 (1.34–1.62) 1.29 (1.17–1.43) 1
21 Pancytopenia 1.58 (1.45–1.73) 1.19 (1.08–1.31) 1
22 Respiratory failure 1.37 (1.14–1.64) 1.31 (1.08–1.59) 1
23 Blood pressure decreased 1.28 (1.18–1.38) 1.22 (1.12–1.33) 1
24 Interstitial lung disease 1.36 (1.29–1.43) 1.10 (1.04–1.16) 1
25 Thrombocytopenia 1.13 (1.00–1.26) 1.29 (1.14–1.45) 1
26 Pneumonia 1.30 (1.19–1.41) 1.11 (1.01–1.22) 2
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Table 3  Adverse drug events (ADEs) categorised as Class 2 (in  ORe descending order)
Underlined ADEs are categorised in a separate Class in the other sex
ORe adjusted odds ratio with elderly as a factor for the occurrence of ADEs, ORp adjusted odds ratio with polypharmacy as a factor for the 
occurrence of ADEs, 95% CI 95% confidence interval of  ORe and  ORp, Female Class class in which ADEs common in females are categorised, 
Male Class class in which ADEs common in males are categorised
(a) Male cases
No. ADEs ORe (95% CI) ORp (95% CI) Female class
1 Urinary retention 3.34 (2.93–3.82) 0.79 (0.69–0.91) 1
2 Fall 2.29 (1.93–2.73) 1.04 (0.87–1.25) 2
3 Cardiac failure 2.17 (1.94–2.43) 1.07 (0.95–1.20) 1
4 Osteonecrosis of jaw 2.14 (1.83–2.52) 0.60 (0.50–0.73) 2
5 Gastrointestinal haemorrhage 2.14 (1.89–2.43) 0.77 (0.67–0.89) 2
6 Pneumonia aspiration 2.14 (1.81–2.52) 1.14 (0.96–1.35) 1
7 Melaena 2.08 (1.78–2.43) 0.91 (0.77–1.07) 2
8 Cerebral haemorrhage 1.88 (1.70–2.07) 0.89 (0.80–0.99) 2
9 Pleural effusion 1.81 (1.54–2.12) 1.00 (0.84–1.18) 2
10 Cerebral infarction 1.79 (1.62–1.97) 0.73 (0.65–0.82) 2
11 Delirium 1.70 (1.49–1.94) 1.01 (0.87–1.16) 2
12 Decreased appetite 1.55 (1.40–1.72) 1.07 (0.96–1.20) 1
13 Platelet count decreased 1.46 (1.37–1.56) 0.97 (0.90–1.04) 2
14 Depressed level of consciousness 1.40 (1.21–1.63) 1.06 (0.90–1.24) 2
15 Pneumonia 1.40 (1.30–1.51) 1.02 (0.94–1.11) 1
16 Lymphoproliferative disorder 1.40 (1.16–1.68) 0.11 (0.06–0.16) 2
17 Death 1.26 (1.10–1.43) 0.62 (0.53–0.73) 2
18 Hypertension 1.25 (1.05–1.50) 0.69 (0.56–0.85) 4
19 Renal impairment 1.17 (1.08–1.26) 1.02 (0.94–1.11) 1
(b) Female cases
No. ADEs ORe (95% CI) ORp (95% CI) Male class
1 Gastrointestinal haemorrhage 3.69 (3.15–4.33) 1.05 (0.90–1.22) 2
2 Melaena 3.22 (2.69–3.86) 0.93 (0.77–1.11) 2
3 Fall 3.05 (2.63–3.54) 0.88 (0.75–1.03) 2
4 Delirium 2.89 (2.47–3.38) 1.11 (0.94–1.29) 2
5 Cerebral haemorrhage 2.61 (2.31–2.97) 0.83 (0.72–0.95) 2
6 Blood creatinine increased 2.16 (1.71–2.73) 1.15 (0.90–1.47) 1
7 Osteonecrosis of jaw 2.16 (1.95–2.39) 0.71 (0.63–0.80) 2
8 Death 1.99 (1.69–2.34) 0.67 (0.55–0.81) 2
9 Cerebral infarction 1.91 (1.71–2.13) 0.63 (0.55–0.72) 2
10 Haemoglobin decreased 1.46 (1.24–1.72) 0.88 (0.73–1.07) 4
11 Lymphoproliferative disorder 1.42 (1.26–1.60) 0.10 (0.07–0.13) 2
12 Infection 1.26 (1.04–1.54) 0.50 (0.38–0.64) 4
13 Platelet count decreased 1.23 (1.15–1.32) 0.97 (0.90–1.06) 2
14 Lung disorder 1.21 (1.01–1.45) 1.06 (0.87–1.30) 1
15 Depressed level of consciousness 1.21 (1.07–1.37) 1.05 (0.91–1.20) 2
16 Pleural effusion 1.20 (1.02–1.43) 1.12 (0.93–1.35) 2
17 Shock 1.20 (1.09–1.32) 0.89 (0.80–1.00) 4
18 Dizziness 1.20 (1.06–1.35) 0.94 (0.82–1.07) 1
19 Stomatitis 1.19 (1.02–1.38) 1.01 (0.85–1.19) 4
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appetite, rhabdomyolysis, cardiac failure, pneumonia) were 
significant for females only.
3.3  ADEs That are Associated with Elderly and Not 
With Polypharmacy: Class 2 [E(+), P(−)]
ADEs categorised as Class 2 are presented by sex in Table 3 
((a) Males, (b) Females). The ADEs in Table 3 were ranked 
in descending  ORe  order. A total of 19 male and female ADE 
types, respectively, were categorised as Class 2. Of these, 
12 were categorised as being common to both males and 
females.  ORe for males presented high values for urinary 
retention (OR 3.34), fall (OR 2.29), cardiac failure (OR 
2.17), osteonecrosis of the jaw (OR 2.14), and gastrointesti-
nal haemorrhage (OR 2.14). For females, high values were 
found for gastrointestinal haemorrhage (OR 3.69), melaena 
(OR 3.22), fall (OR 3.05), delirium (OR 2.89), and cerebral 
haemorrhage (OR 2.61). Except for mental and nervous dis-
orders, various ADEs were categorised in Class 2. Hyperten-
sion was common to males, while decreased haemoglobin, 
infection, shock and stomatitis were common to females.
3.4  ADEs That are Associated with Polypharmacy 
and Not With Elderly: Class 3 [E(−), P(+)]
Class 3 ADEs are presented by sex in Table 4 ((a) Males, (b) 
Females). ADEs in Table 4 and  ORp are ranked in descend-
ing order. In total, 14 and 20 ADE types common to both 
males and females, respectively, were categorised as Class 
3. Of these, nine were common to both males and females.
ORp for males included drug interaction (OR 2.16), 
agranulocytosis (OR 1.62), rhabdomyolysis (OR 1.60), 
erythema (OR 1.41), and toxic skin eruption (OR 1.31). For 
females, the ranking was sepsis (OR 1.60), cellulitis (OR 
1.48), hyperglycaemia (OR 1.47), neuroleptic malignant 
syndrome (OR 1.45), and erythema (OR 1.39).
In Class 3, the PTs infectious diseases and decreased 
white blood cell count predominated. Septic shock and 
decreased white blood cell count were categorised as com-
mon to males, while sepsis, cellulitis, hyperglycaemia, 
acute pancreatitis, increased blood creatine phosphokinase, 
Stevens–Johnson syndrome, jaundice, increased aspartate 
aminotransferase, toxic epidermal necrolysis, vomiting, and 
drug-induced liver injury were categorised as common to 
females.
3.5  ADEs That are Not Associated with Either 
Polypharmacy or Elderly: Class 4 [E(−), P(−)]
Class 4 ADEs are presented by sex in Table 5 ((a) Males, 
(b) Females).  ORe and  ORp volumes are ranked in ascending 
order to clarify that ADEs were unaffected by elderly or 
polypharmacy. A total of 48 and 35 ADE types were cat-
egorised as male and female, respectively. Of these, 32 were 
common to both sexes. Class 4 ADEs were dominated by 
allergic symptoms, including anaphylactic reaction.
3.6  Summary of the Results
ADE classes are presented in Fig. 3.
4  Discussion
Class 2 ADEs [E(+), P(−)], including the PTs delirium 
and fall, have previously been identified as those with a 
high risk of occurrence in elderly patients treated with 
polypharmacy [10]. However, these ADEs were associated 
with the elderly but not with polypharmacy in this study. 
Moreover, it is difficult to distinguish between symptoms 
associated with drugs and those associated with aging, 
and symptoms may actually include symptoms of aging.
Conversely, the results of the present study support 
existing reports that the risk of Class 1 ADEs [E(+), P(+)], 
including electrolyte abnormalities [15–17], renal disorder 
[3] and pneumonia aspiration [18, 19], in elderly patients 
treated with polypharmacy is high. Dehydration and elec-
trolyte imbalance are common in elderly persons, who 
have a high threshold value for throat dryness; moreover, 
polypharmacy including diuretics and selective serotonin 
receptor inhibitors has been reported [15–17] to increase 
these risks. In addition to the reduction in renal function 
associated with the elderly [3], multi-drug combinations of 
non-steroidal anti-inflammatory drugs, hypotensive drugs 
and diuretics have been reported to increase the risk of 
renal disorders. Similarly, reduced mobility in the elderly 
leads to decreased swallowing function, and multi-drug 
combinations including those with muscle-relaxing prop-
erties and diuretics carry a risk of pneumonia aspiration 
[18, 19].
The PTs decreased white blood cell count and infectious 
diseases predominate among the Class 3 ADEs [E(−), 
P(+)] that are common to both sexes. This indicates that 
there is an age-independent risk of myelosuppression with 
combinations of anti-cancer agents, which subsequently 
increase the risk of infections. In addition, given that many 
Class 4 ADEs [E(−), P(−)] were found to be allergic in 
nature, the high risk of allergy-type ADEs unrelated to 
polypharmacy or elderly should be considered.
In this study, sex differences in the occurrence of ADEs 
were investigated. ADEs of which the risk of onset is 
associated with polypharmacy occurred more frequently 
in women (Tables 2, 3), which may suggest that women 
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are more sensitive to the effects of polypharmacy than 
are men [20, 21]. However, the type of drug used was not 
included in the analysis conditions. Thus, detailed inves-
tigations focusing on the types of drugs used are neces-
sary for a detailed discussion on the reasons for these sex 
differences.
This study has the following limitations: since this study 
focused on the 100 most common ADE types reported in 
the JADER database, it is possible that ADEs categorised 
as Class 1 were not the only events that carry a high risk 
of occurrence in elderly patients treated with polyphar-
macy: other ADEs may carry a high risk of occurrence in 
Table 4  Adverse drug events (ADEs) categorised as Class 3 (in  ORp descending order)
Underlined ADEs are categorised in a separate Class in the other sex
ORe adjusted odds ratio with elderly as a factor for the occurrence of ADEs, ORp adjusted odds ratio with polypharmacy as a factor for the 
occurrence of ADEs, 95% CI 95% confidence interval of  ORe and  ORp, Female Class class in which ADEs common in females are categorised, 
Male Class class in which ADEs common in males are categorised
(a) Male cases
No. ADEs ORe (95% CI) ORp (95% CI) Female class
1 Drug interaction 1.05 (0.91–1.21) 2.16 (1.87–2.49) 1
2 Agranulocytosis 0.69 (0.60–0.79) 1.62 (1.42–1.84) 3
3 Rhabdomyolysis 0.86 (0.80–0.93) 1.60 (1.48–1.73) 1
4 Erythema 0.91 (0.78–1.06) 1.41 (1.20–1.66) 3
5 Toxic skin eruption 0.69 (0.57–0.84) 1.31 (1.07–1.60) 3
6 Septic shock 0.80 (0.66–0.97) 1.28 (1.05–1.55) 4
7 Electrocardiogram qt prolonged 1.17 (0.98–1.39) 1.25 (1.04–1.49) 1
8 Anaphylactic shock 0.70 (0.67–0.74) 1.22 (1.15–1.28) 3
9 Neuroleptic malignant syndrome 0.31 (0.26–0.35) 1.19 (1.05–1.34) 3
10 Hepatic function abnormal 0.88 (0.83–0.93) 1.17 (1.11–1.25) 3
11 Drug eruption 0.71 (0.65–0.78) 1.16 (1.05–1.27) 3
12 Disseminated intravascular coagulation 1.11 (0.98–1.25) 1.16 (1.01–1.32) 3
13 Pyrexia 0.87 (0.82–0.94) 1.13 (1.05–1.22) 3
14 White blood cell count decreased 0.88 (0.80–0.97) 1.11 (1.01–1.23) 4
(b) Female cases
No. ADEs ORe (95% CI) ORp (95% CI) Male class
1 Sepsis 0.91 (0.79–1.05) 1.60 (1.38–1.84) 4
2 Cellulitis 1.13 (0.93–1.38) 1.48 (1.20–1.81) 4
3 Hyperglycaemia 0.90 (0.75–1.08) 1.47 (1.22–1.77) 4
4 Neuroleptic malignant syndrome 0.49 (0.42–0.57) 1.45 (1.26–1.67) 3
5 Erythema 0.62 (0.54–0.72) 1.39 (1.20–1.59) 3
6 Pancreatitis acute 0.65 (0.54–0.78) 1.38 (1.14–1.66) 4
7 Disseminated intravascular coagulation 1.06 (0.92–1.22) 1.38 (1.19–1.59) 3
8 Blood creatine phosphokinase increased 0.92 (0.79–1.07) 1.34 (1.14–1.57) 4
9 Toxic skin eruption 0.75 (0.63–0.89) 1.31 (1.09–1.56) 3
10 Stevens-Johnson syndrome 0.70 (0.63–0.77) 1.29 (1.16–1.42) 4
11 Jaundice 1.04 (0.88–1.24) 1.26 (1.05–1.51) 4
12 Aspartate aminotransferase increased 0.87 (0.74–1.03) 1.24 (1.04–1.47) 4
13 Toxic epidermal necrolysis 0.81 (0.70–0.93) 1.23 (1.06–1.42) 4
14 Anaphylactic shock 0.68 (0.64–0.72) 1.19 (1.12–1.27) 3
15 Vomiting 1.11 (1.00–1.22) 1.18 (1.05–1.31) 4
16 Drug-induced liver injury 0.57 (0.50–0.65) 1.15 (1.01–1.31) 4
17 Pyrexia 0.74 (0.69–0.80) 1.14 (1.06–1.23) 3
18 Agranulocytosis 0.62 (0.55–0.69) 1.13 (1.01–1.26) 3
19 Drug eruption 0.61 (0.56–0.67) 1.12 (1.03–1.22) 3
20 Hepatic function abnormal 0.79 (0.75–0.84) 1.09 (1.02–1.16) 3
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Table 5  Adverse drug events (ADEs) categorised as Class 4  (ORe and  ORp volumes in ascending order)
(a) Male cases
No. ADEs ORe (95% CI) ORp (95% CI) Female class
1 Cytomegalovirus infection 0.33 (0.26–0.41) 0.74 (0.60–0.92) 4
2 Drug reaction with eosinophilia and systemic symptoms 0.37 (0.33–0.42) 0.77 (0.68–0.88) 4
3 Diabetes mellitus 0.49 (0.41–0.59) 0.65 (0.53–0.79) 4
4 Headache 0.44 (0.33–0.56) 0.85 (0.65–1.09) 4
5 Tubulointerstitial nephritis 0.53 (0.44–0.63) 0.74 (0.61–0.88) 4
6 Palmar-plantar erythrodysaesthesia syndrome 0.95 (0.75–1.19) 0.44 (0.31–0.59) 4
7 Anaphylactoid reaction 0.43 (0.37–0.51) 1.15 (0.99–1.34) 4
8 Anaphylactic reaction 0.51 (0.46–0.56) 1.02 (0.92–1.13) 4
9 Pancreatitis acute 0.50 (0.42–0.59) 1.04 (0.88–1.22) 3
10 Peritonitis 0.69 (0.57–0.84) 0.79 (0.63–0.97) 4
11 Urticaria 0.52 (0.45–0.60) 1.09 (0.94–1.26) 4
12 Neutrophil count decreased 0.92 (0.84–1.01) 0.65 (0.58–0.73) 4
13 Infection 0.99 (0.82–1.19) 0.61 (0.48–0.76) 2
14 Drug-induced liver injury 0.74 (0.65–0.84) 0.84 (0.72–0.96) 3
15 Pulmonary embolism 0.58 (0.47–0.72) 1.11 (0.89–1.37) 4
16 Pneumocystis jirovecii pneumonia 0.90 (0.78–1.04) 0.72 (0.61–0.85) 4
17 Stevens-Johnson syndrome 0.62 (0.56–0.69) 1.06 (0.95–1.18) 3
18 Deep vein thrombosis 0.70 (0.56–0.86) 0.95 (0.75–1.18) 4
19 Rash generalised 0.78 (0.66–0.92) 0.85 (0.71–1.02) 4
20 Erythema multiforme 0.73 (0.64–0.83) 0.92 (0.80–1.05) 4
21 Alanine aminotransferase increased 0.75 (0.64–0.87) 0.90 (0.76–1.06) 4
22 Bone marrow failure 0.99 (0.88–1.11) 0.68 (0.59–0.79) 4
23 Neutropenia 0.84 (0.75–0.92) 0.81 (0.72–0.91) 4
24 Rash 0.67 (0.60–0.74) 1.02 (0.92–1.14) 4
25 Leukopenia 0.85 (0.73–0.98) 0.82 (0.70–0.97) 4
26 Blood creatine phosphokinase increased 0.66 (0.59–0.74) 1.06 (0.94–1.20) 3
27 Stomatitis 0.88 (0.75–1.03) 0.80 (0.66–0.96) 2
28 Toxicity to various agents 0.64 (0.54–0.76) 1.15 (0.96–1.37) 4
29 Seizure 0.77 (0.69–0.85) 0.98 (0.87–1.09) 4
30 Liver disorder 0.78 (0.72–0.84) 1.04 (0.96–1.12) 4
31 Hyperglycaemia 0.84 (0.71–0.99) 0.97 (0.80–1.16) 3
32 Shock 0.97 (0.89–1.06) 0.87 (0.78–0.96) 2
33 Toxic epidermal necrolysis 0.73 (0.63–0.84) 1.16 (1.00–1.35) 3
34 Aspartate aminotransferase increased 0.83 (0.71–0.96) 1.02 (0.86–1.21) 3
35 Nausea 0.87 (0.76–0.98) 1.00 (0.87–1.14) 4
36 Diarrhoea 0.97 (0.88–1.07) 0.94 (0.84–1.04) 4
37 Herpes zoster 0.81 (0.63–1.04) 1.13 (0.87–1.47) 4
38 Febrile neutropenia 1.04 (0.93–1.15) 0.89 (0.79–1.00) 4
39 Sepsis 0.86 (0.76–0.98) 1.08 (0.94–1.23) 3
40 Malaise 1.02 (0.89–1.16) 0.93 (0.80–1.08) 4
41 Loss of consciousness 1.10 (0.99–1.22) 0.90 (0.80–1.01) 4
42 Haemoglobin decreased 1.17 (1.00–1.38) 0.84 (0.70–1.01) 2
43 Ileus 1.05 (0.88–1.25) 0.96 (0.79–1.16) 4
44 Renal disorder 1.05 (0.92–1.20) 0.97 (0.83–1.12) 1
45 Jaundice 1.05 (0.90–1.22) 0.97 (0.82–1.14) 3
46 Cellulitis 0.90 (0.71–1.14) 1.14 (0.89–1.46) 3
47 Vomiting 1.00 (0.88–1.14) 1.13 (0.98–1.29) 3
48 Dyspnoea 1.05 (0.94–1.16) 1.11 (0.99–1.23) 4
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polypharmacy-treated patients. In addition, because ADEs 
were categorised using only basic data (age, sex and num-
ber of concomitant drugs) in the JADER, questions as to 
whether Class 1-categorised ADEs were really caused by 
polypharmacy, or whether other factors (e.g. background 
diseases or individual drugs) were involved highlight the 
need for studies from both pharmacological and physi-
ological perspectives.
In conclusion, analysis of ADEs considering polyphar-
macy and the elderly revealed that the risk of the 100 most 
common ADEs reported in the JADER database could be 
categorised as follows: electrolyte abnormalities, renal and 
respiratory disorders, and coagulopathy in Class 1 [E(+), 
P(+)]; delirium, falls in Class 2 [E(+), P(−)]; myelosup-
pression arising from anti-cancer multi-drug combinations 
in Class 3 [E(−), P(+)]; and allergy-type ADEs in Class 
ORe adjusted odds ratio with elderly as a factor for the occurrence of ADEs, ORp adjusted odds ratio with polypharmacy as a factor for the 
occurrence of ADEs, 95% CI 95% confidence interval of  ORe and  ORp, Female Class class in which ADEs common in females are categorised, 
Male Class class in which ADEs common in males are categorised
Table 5  (continued)
(a) Female cases
No. ADEs ORe (95% CI) ORp (95% CI) Male class
1 Headache 0.31 (0.25–0.37) 0.59 (0.49–0.71) 4
2 Anaphylactoid reaction 0.36 (0.30–0.42) 1.03 (0.88–1.21) 4
3 Cytomegalovirus infection 0.46 (0.36–0.57) 0.84 (0.66–1.06) 4
4 Anaphylactic reaction 0.39 (0.35–0.43) 1.00 (0.90–1.10) 4
5 Palmar-plantar erythrodysaesthesia syndrome 0.79 (0.61–1.02) 0.51 (0.36–0.71) 4
6 Pulmonary embolism 0.55 (0.47–0.64) 0.81 (0.69–0.95) 4
7 Drug reaction with eosinophilia and systemic symptoms 0.47 (0.41–0.53) 0.98 (0.86–1.11) 4
8 Neutrophil count decreased 0.73 (0.65–0.81) 0.64 (0.56–0.73) 4
9 Neutropenia 0.61 (0.54–0.68) 0.82 (0.73–0.93) 4
10 Deep vein thrombosis 0.70 (0.61–0.81) 0.72 (0.61–0.85) 4
11 Urticaria 0.49 (0.42–0.56) 1.07 (0.93–1.23) 4
12 Febrile neutropenia 0.61 (0.53–0.70) 0.87 (0.75–1.00) 4
13 Diabetes mellitus 0.54 (0.44–0.66) 1.00 (0.82–1.23) 4
14 Tubulointerstitial nephritis 0.65 (0.54–0.78) 0.85 (0.69–1.05) 4
15 Rash 0.56 (0.51–0.61) 1.05 (0.96–1.16) 4
16 Erythema multiforme 0.71 (0.64–0.80) 0.84 (0.74–0.94) 4
17 Seizure 0.71 (0.65–0.79) 0.84 (0.75–0.95) 4
18 Malaise 0.70 (0.61–0.79) 0.94 (0.81–1.08) 4
19 Peritonitis 0.79 (0.65–0.96) 0.84 (0.66–1.04) 4
20 Hypertension 0.88 (0.73–1.06) 0.76 (0.60–0.94) 2
21 Bone marrow failure 1.07 (0.95–1.21) 0.66 (0.56–0.76) 4
22 Leukopenia 0.71 (0.61–0.82) 1.00 (0.85–1.17) 4
23 Liver disorder 0.73 (0.68–0.79) 0.97 (0.90–1.06) 4
24 Toxicity to various agents 0.69 (0.59–0.80) 1.05 (0.89–1.23) 4
25 Dyspnoea 0.78 (0.70–0.86) 1.00 (0.89–1.12) 4
26 Rash generalised 0.82 (0.72–0.95) 1.05 (0.90–1.22) 4
27 Nausea 0.89 (0.80–0.99) 0.98 (0.88–1.10) 4
28 Herpes zoster 0.85 (0.70–1.02) 1.06 (0.86–1.30) 4
29 Alanine aminotransferase increased 0.81 (0.69–0.95) 1.12 (0.94–1.32) 4
30 White blood cell count decreased 0.87 (0.80–0.95) 1.05 (0.95–1.16) 3
31 Loss of consciousness 0.99 (0.90–1.09) 0.93 (0.83–1.03) 4
32 Diarrhoea 0.92 (0.83–1.01) 1.04 (0.93–1.16) 4
33 Ileus 1.16 (0.95–1.42) 0.86 (0.68–1.07) 4
34 Septic shock 0.86 (0.71–1.05) 1.22 (0.99–1.49) 3
35 Pneumocystis jirovecii pneumonia 1.07 (0.95–1.20) 1.04 (0.91–1.18) 4
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4 [E(−), P(−)]. These categories may provide potentially 
beneficial information for the future pharmaceutical man-
agement of elderly patients. In particular, the grouping of 
some ADEs into Class 2 that are considered classifiable 
as Class 1 in existing reports highlights the need for stud-
ies from pharmacological and physiological perspectives. 
In this study, we grouped ADEs by age (elderly—≥ 70 
year) and polypharmacy (six or more agents) without 
specifying the drugs. Since the risk of ADEs grouped in 
Class 1 increased in the elderly using six or more drugs, 
monitoring is particularly important for elderly patients 
under polypharmacy. However, the risk of Class 2 ADEs 
increased in the elderly who were taking fewer than five 
drugs, and Class 2 ADEs should therefore always be moni-
tored very cautiously in the elderly. Further investigations 
that focus on drug types are warranted.
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Fig. 3  Typical adverse drug 
events (ADEs) categorised into 
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for the occurrence of ADEs, 
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polypharmacy as a factor for 
the occurrence of ADEs. E(+), 
P(+): ADEs where  ORe and 
 ORp significantly exceeded 1; 
E(+), P(−): ADEs where only 
 ORe significantly exceeded 1; 
E(−), P(+): ADEs where only 
 ORp significantly exceeded 1; 
E(−), P(−): ADEs where nei-
ther  ORe nor  ORp significantly 
exceeded 1
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